Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:03 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 9,123 matching trials from the live ClinicalTrials.gov search.
Filters: Tampa, Florida Clear all
Completed Phase 3 Interventional Results available

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

NCT01584648
View directory record Official record
Conditions
Melanoma
Interventions
Dabrafenib, Trametinib, Trametinib placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
19
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Nov 3, 2026, 11:03 AM EST
Recruiting Phase 2 Interventional

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

NCT05882058
View directory record Official record
Conditions
Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
Interventions
BI 764532, dose 1, BI 764532, dose 2, Ventana DLL3 RxDx assay
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
16
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Nov 3, 2026, 11:03 AM EST
Completed Phase 2 Interventional Results available

A Study of LY3451838 in Participants With Migraine

NCT04498910
View directory record Official record
Conditions
Migraine
Interventions
LY3451838, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Phoenix, Arizona • Stamford, Connecticut • Ocala, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Nov 3, 2026, 11:03 AM EST
Completed No phase listed Observational

International Ataxia Rating Scale in Younger Patients

NCT01942850
View directory record Official record
Conditions
Ataxia Telangiectasia
Interventions
Not listed
Lead sponsor
Quince Therapeutics S.p.A.
Industry
Eligibility
6 Years to 18 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 31, 2014 · Synced Nov 3, 2026, 11:03 AM EST
Completed Phase 3 Interventional Results available

Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus

NCT02794285
View directory record Official record
Conditions
Active Systemic Lupus Erythematosus
Interventions
Anifrolumab, Placebo
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
62
States / cities
Birmingham, Alabama • El Cajon, California • Hemet, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Nov 3, 2026, 11:03 AM EST
Recruiting Phase 3 Interventional

NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

NCT07114874
View directory record Official record
Conditions
Schizophrenia
Interventions
NBI-1117568
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
50
States / cities
Bryant, Arkansas • Little Rock, Arkansas • Cerritos, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 3, 2026, 11:03 AM EST
Completed Phase 1 Interventional

Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer

NCT00080418
View directory record Official record
Conditions
Neoplasm
Interventions
Liposome Entrapped Paclitaxel Easy to Use
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
3
States / cities
Tampa, Florida • New Brunswick, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 4, 2011 · Synced Nov 3, 2026, 11:03 AM EST
Active, not recruiting Phase 3 Interventional

Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)

NCT04365374
View directory record Official record
Conditions
Brain Metastases
Interventions
Gamma Tile-Surgically Targeted Radiation Therapy (STaRT), Stereotactic Radiation Therapy
Device · Radiation
Lead sponsor
GT Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
37
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Jacksonville, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Nov 3, 2026, 11:03 AM EST
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis

NCT03358290
View directory record Official record
Conditions
Plaque Psoriasis, Skin Diseases
Interventions
JTE-051, Placebo
Drug
Lead sponsor
Shionogi Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
12
States / cities
Fountain Valley, California • Fremont, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Nov 3, 2026, 11:03 AM EST
Active, not recruiting Phase 1Phase 2 Interventional Results available

Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)

NCT02638090
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer
Interventions
Vorinostat, Pembrolizumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 3, 2026, 11:03 AM EST
Completed Phase 3 Interventional Results available

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

NCT03078478
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Insulin degludec, Insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
156
States / cities
Anniston, Alabama • Birmingham, Alabama • Chandler, Arizona + 135 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Nov 3, 2026, 11:03 AM EST
Completed Phase 2 Interventional

Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia

NCT00003808
View directory record Official record
Conditions
Leukemia
Interventions
theophylline
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
68
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 51 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Nov 3, 2026, 11:03 AM EST
Recruiting Phase 3 Interventional

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

NCT05219617
View directory record Official record
Conditions
Seizures, Lennox Gastaut Syndrome
Interventions
Carisbamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
22
States / cities
Palo Alto, California • Jacksonville, Florida • Orlando, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Nov 3, 2026, 11:03 AM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1

NCT04886518
View directory record Official record
Conditions
Myotonic Dystrophy 1, Excessive Daytime Sleepiness
Interventions
Pitolisant Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Irvine, California • Aurora, Colorado • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 3, 2026, 11:03 AM EST
Terminated Phase 2 Interventional Results available

An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.

NCT02316847
View directory record Official record
Conditions
Epilepsy
Interventions
diazepam nasal spray
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
12 Years to 65 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
33
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Nov 3, 2026, 11:03 AM EST
Completed Phase 1 Interventional

Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide

NCT00006047
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Oral Etoposide, Oral 9-Nitrocamptothecin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 26, 2012 · Synced Nov 3, 2026, 11:03 AM EST
Terminated Phase 2 Interventional Results available

A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression

NCT03044249
View directory record Official record
Conditions
Psychosis, Dementia, Aggression, Agitation, Alzheimer Dementia
Interventions
MP-101, Placebo
Drug
Lead sponsor
Mediti Pharma Inc.
Other
Eligibility
50 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Pasadena, California • Fairfield, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Nov 3, 2026, 11:03 AM EST
Completed Not applicable Interventional

Motivational Enhancement System for Adherence

NCT01009749
View directory record Official record
Conditions
HIV
Interventions
Motivational Enhancement System for Adherence (MESA), Motivational Enhancement System for Health (MESH)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 24 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Nov 3, 2026, 11:03 AM EST
Completed Phase 3 Interventional Results available

OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)

NCT05139810
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Donidalorsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Scottsdale, Arizona • San Diego, California • Santa Monica, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Nov 3, 2026, 11:03 AM EST
Completed Phase 2 Interventional Results available

Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens

NCT01721759
View directory record Official record
Conditions
Squamous Cell Non-small Cell Lung Cancer
Interventions
Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
20
States / cities
Sacramento, California • San Diego, California • Tampa, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Nov 3, 2026, 11:03 AM EST
Active, not recruiting Phase 2 Interventional

A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's

NCT06928142
View directory record Official record
Conditions
Sjogren Disease
Interventions
Sibeprenlimab, Placebo
Biological · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Riverside, California • Tujunga, California • Brandon, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 3, 2026, 11:03 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine

NCT05871541
View directory record Official record
Conditions
Herpes Zoster (HZ), Shingles, Infectious Disease
Interventions
JCXH-105, Active Control (Shingrix)
Biological
Lead sponsor
Immorna Biotherapeutics, Inc.
Industry
Eligibility
50 Years to 69 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Hollywood, Florida • Tampa, Florida • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 3, 2026, 11:03 AM EST
Completed Phase 2 Interventional

HT-0712 vs. Placebo in Subjects With Age-Associated Memory Impairment (AAMI)

NCT02013310
View directory record Official record
Conditions
Age-Associated Memory Impairment (AAMI)
Interventions
HT-0712, Placebo
Drug
Lead sponsor
Dart NeuroScience, LLC
Industry
Eligibility
50 Years to 80 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
16
States / cities
Sun City, Arizona • Long Beach, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Nov 3, 2026, 11:03 AM EST
Completed Phase 2 Interventional

An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type

NCT00153010
View directory record Official record
Conditions
Alzheimer Disease
Interventions
NS 2330 (Tesofensine)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 85 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
80
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Nov 3, 2026, 11:03 AM EST